- Study: Counting carbs can improve quality of life in Type 1 diabetes patients on insulin pump therapy
- Adherence among chronic disease patients can lead to big savings
- Mylan's generic Precose gets green light from FDA
- Combining Lilly and Amylin drug with insulin intake found to promote weight loss
- Lilly, JDRF enter research agreement
INDIANAPOLIS — Patients with Type 1 diabetes using an insulin product made by Eli Lilly can store it in their pumps for longer periods of time, while children using it have additional options, thanks to a labeling change approved Wednesday by the Food and Drug Administration.
The FDA approved changes to the labeling of Humalog (insulin lispro [rDNA origin]) that allows continuous insulin infusion pump therapy in children ages 4 years and older with Type 1 diabetes. Additionally, the insulin can remain in the external pump reservoir for seven days, and patients now can wait three days before changing the infusion set and infusion set insertion site, Lilly said.
“Insulin pumps can be an additional option for people using rapid-acting insulin, and allow people to manage their Type 1 diabetes around their lifestyle,” Lilly clinical research physician Dana Hardin stated. “These Humalog label updates reflect Lilly Diabetes’ commitment to providing people with personalized solutions that meet their everyday needs.”